相关实验视频

Updated: Jun 18, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

吉尔特里尼布降低了急性髓性白血病细胞中的FLT3表达

Thị Lam Thái¹, Sun-Young Han¹

¹College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju 52828, Republic of Korea.

Biomolecules & therapeutics

|August 2, 2024

概括

吉尔特里尼布治疗降低了急性髓性白血病 (AML) 细胞中的FLT3表达和酸化. 这种降低通过后转录机制发生,并且也在其他FLT3抑制剂中观察到.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

急性髓性白血病 (AML) 是一种复杂的癌症,经常出现FLT3基因突变.
吉尔特里尼布是一种FDA批准的FLT3抑制剂,用于复发性/耐药性AML.
了解吉尔特里尼布的精确机制对于管理耐药性和识别生物标志物至关重要.

研究的目的:

调查吉尔特里尼布对AMLFLT3表达水平的影响.
探索基尔特里尼布诱导的FLT3减少背后的监管机制.
评估其他FLT3抑制剂是否具有这种作用.

主要方法:

用不同剂量的吉尔特利尼布治疗AML细胞系.
随着时间的推移,对FLT3酸化和表达水平的分析.
对FLT3mRNA转录的评估.
评估其他FLT3抑制剂 (米多斯塔林,克雷诺拉尼布,奎萨丁尼布).

主要成果:

吉尔特里尼布诱导FLT3酸化和表达的剂量依赖性下降.
在48小时后,FLT3表达的减少最为显著.
FLT3 减少独立于mRNA转录,表明转录后调节.
其他FLT3抑制剂也减少了FLT3的表达.

结论:

吉尔特里尼布通过转录后机制减少FLT3的表达.
这种效应与其他FLT3抑制剂相同,表明一种共同的途径.
这些发现可能有助于优化吉尔特里尼布治疗和了解AML的耐药性.
需要进一步的研究来充分阐明临床影响.

关键词:

急性骨髓性白血病 (AML) 是一种急性骨髓性白血病.它具有抗白血病活性.FLT3 FLT3 在线播放在FLT3表达式中,吉尔特里尼尼布的使用方法激酶抑制剂的使用

更多相关视频

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...